Current partner codePEPTIDESDE
NCT04445857·Phase 4·INTERVENTIONAL

Efficacy of Coadministration of Calcitonin and Hyperbaric Bupivacaine in Spinal Anesthesia in Tramadol-abuse Patients

Status

Completed

Phase

Phase 4

Enrollment

90

Locations

1

Results

Not posted

Publications

1

Study summary

What the protocol is testing.

Increasing duration of local anesthetic action is desired for prolongation of postoperative patient comfort, as well as decreasing perioperative opioid consumption and subsequent side effects. Calcitonin, discovered in 1961, has been established, synthesized, and developed for use in treating disease. In 1983 it was demonstrated that calcitonin is an analgesic, which is also effective in the epidural and subarachnoid spaces.Tramadol abuse has dramatically increased in Egypt since 2008 and has led to many admissions to addiction treatment centers.It was shown that the duration of sensory block of spinal anesthesia with hyperbaric bupivacaine in chronic opium abusers undergoing lower extremity orthopedic surgery was much shorter in chronic opium abusers compared with non-abusers.

Interventions

Treatment arms and agents.

DRUG

Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml) intrathecally

coadministration of calcitonin intrathecally and a single-shot hyperbaric bupivacaine

DRUG

Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml) intravenously

coadministration of calcitonin intravenously and a single-shot hyperbaric bupivacaine

OTHER

Normal Saline (NS)

coadministration of normal saline and a single-shot hyperbaric bupivacaine

Timeline

From registration to results.

  1. First posted

    Jun 24, 2020

  2. Study start

    Sep 1, 2020

  3. Primary completion

    Jan 31, 2021

  4. Study completion

    Jan 31, 2021

  5. Results posted

    Not reported

  6. Registry updated

    Apr 8, 2025

Outcomes

What the study measures.

Primary outcomes

The total dose of rescue analgesia (mg)

Time frame · The first 24 hours after surgery

The total dose of rescue analgesia (mg)

Secondary outcomes

Not reported in the indexed record.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
60 Years
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Patients with history of tramadol addiction (single drug addiction) and duration of addiction \>1 year * Elective lower abdomen or lower extremities surgeries under spinal anesthesia * ASA physical status I and II Exclusion Criteria: * Patient's refusal, * duration of surgery more than 120 min, * obesity with body mass index (BMI) \>35 kg/m2, * generalized infection or localized infection at level of blockade, * neurological disease, * psychological disorder * coagulation disorder, * history of uncontrolled hypertension, * history of uncontrolled blood sugar, * allergy to bupivacaine or calcitonin

Study locations

1 registered sites.

Egypt. Showing up to 24 locations stored in the fast local snapshot.

Ain-Shams University Hospitals

Cairo, Egypt

Related trials

More studies on Calcitonin.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.